Kitazato

Kitazato CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Kitazato (368A.T) as of Nov 17, 2026 is 25.61 %. In the previous year, CapEx to Operating Cash Flow Ratio was 1.89 % — a change of 1,256.11% (higher).

CapEx/OCF

25.61 %

YoY

1,256.11%

Last updated:

CapEx to Operating Cash Flow Ratio of Kitazato is 2025 25.61 % . CapEx to Operating Cash Flow Ratio of Kitazato was 2024 1.89 % . It decreases by 1,256.11% higher compared to the previous year.

The Kitazato CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2023
3.76 JPY
Jan 1, 2024
1.89 JPY
Jan 1, 2025
25.61 JPY
The Kitazato CapEx/OCF history
YEARCapEx/OCFYoY
25.61 %+1,256.11%
1.89 %-49.72%
3.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

CapEx to Operating Cash Flow Ratio of Kitazato is 25.61 % in 2025.

CapEx to Operating Cash Flow Ratio of Kitazato changed from 1.89 % to 25.61 %, representing a 1,256.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Kitazato since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Kitazato with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Kitazato

All Key Metrics — Kitazato